Rhumbline Advisers Has $60.42 Million Stock Position in Humana Inc. (NYSE:HUM)

Rhumbline Advisers lessened its position in Humana Inc. (NYSE:HUM) by 3.8% in the fourth quarter, HoldingsChannel reports. The fund owned 238,128 shares of the insurance provider’s stock after selling 9,522 shares during the quarter. Rhumbline Advisers’ holdings in Humana were worth $60,415,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Atlas Brown Inc. grew its stake in Humana by 0.6% in the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after acquiring an additional 38 shares during the period. Moors & Cabot Inc. grew its stake in Humana by 2.5% in the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after acquiring an additional 40 shares during the period. Mather Group LLC. grew its stake in Humana by 21.0% in the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock valued at $60,000 after acquiring an additional 41 shares during the period. OLD National Bancorp IN grew its stake in Humana by 1.8% in the third quarter. OLD National Bancorp IN now owns 2,613 shares of the insurance provider’s stock valued at $828,000 after acquiring an additional 45 shares during the period. Finally, Your Advocates Ltd. LLP grew its stake in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on HUM shares. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Barclays raised their target price on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday. TD Cowen raised their target price on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a report on Monday, November 4th. Morgan Stanley dropped their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Finally, Truist Financial raised their target price on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $293.05.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.32% of the stock is owned by company insiders.

Humana Stock Performance

NYSE:HUM opened at $253.61 on Monday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The business has a fifty day simple moving average of $271.27 and a two-hundred day simple moving average of $293.44. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The company has a market capitalization of $30.54 billion, a P/E ratio of 22.46, a P/E/G ratio of 2.11 and a beta of 0.56.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, analysts expect that Humana Inc. will post 16.11 earnings per share for the current year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.